DUPIXENT Adds COPD to Its Portfolio with First Biologic Approval
DUPIXENT (dupilumab), developed by Sanofi and Regeneron, has added another significant achievement to its portfolio by receiving the first-ever biologic approval for treating Chronic Obstructive Pulmonary Disease (COPD).
